Skip to main content

Table 2 Medication use in the prior 12-month period for patients initiating therapy with duloxetine versus venlafaxine XR.

From: Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder

Previous Medication Use

Duloxetine Group, %

(n = 9,641)

Venlafaxine XR Group, %

(n = 8,514)

p-value

Antidepressants

   

   SSRIs

59.5

52.7

.0001

   TCAs

12.6

7.8

.0001

   MAOIs

0.2

0.1 (NS)

.275

   Other antidepressants

45.0

36.5

.0001

Anxiolytics

57.0

47.4

.0001

   Benzodiazepines

53.8

44.5

.0001

   Buspirone

4.8

4.1 (NS)

.015

   Hydroxyzine

5.7

4.9 (NS)

.009

Anticonvulsants

30.1

17.9

.0001

Antipsychotics

20.0

15.4

.0001

   Atypical

17.8

13.2

.0001

   Typical

3.5

2.9 (NS)

.021

Analgesics

63.1

51.3

.0001

Skeletal-muscle relaxants

26.5

17.1

.0001

Antimigraine medications

12.3

9.2

.0001

Hypnotics

30.2

22.3

.0001

Other medications

   

   Antiulcer drugs

29.4

22.7

.0001

   Antihyperlipidemics

20.0

15.5

.0001

   Antihypertensives

17.9

13.9

.0001

   Antiasthmatics

17.7

15.4

.0001

   ADHD medications

   

Stimulants

13.6

9.2

.0001

Atomoxetine

2.0

1.7 (NS)

.079

   Antihistamines

10.3

6.7

.0001

   β-Adrenoceptor blockers

8.9

7.3

.0001

   Antidiabetics

9.0

6.7

.0001

   Antimanics

3.0

2.3

.001

≥3 unique antidepressants

20.8

16.6

.0001

≥3 unique pain medications

25.5

15.6

.0001

  1. XR = extended release; SSRIs = selective serotonin reuptake inhibitors; TCAs = tricyclic antidepressants; MAOIs = monoamine oxidase inhibitors; ADHD = attention-deficit/hyperactivity disorder. All comparisons of medication use between cohorts are statistically significant at least P < 0.001), except those marked by (NS = Not statistically significant).